A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
← catalyst calendarSponsored by ADC Therapeutics S.A. (industry) · ADCT — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
128actual
Sites
14
Countries
France, Spain, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decided to halt further development of ADCT-601
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-13 | actual | When the study began enrolling |
| Primary completion | 2025-04-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-17 | actual | The whole study's end, after follow-up |
| First posted | 2022-05-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: ADCT-601 — also filed as Mipasetamab uzoptirine
- Drug: Gemcitabine
Primary outcomes
what the primary-completion date above is the date OFSafety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs)
measured Up to approximately 2 years
Number of Participants who Experience a Dose Limiting Toxicity (DLT)
measured Day 1 to Day 21
Number of Participants who Experience a Dose Interruption
measured Up to approximately 2 years
Number of Participants who Experience a Dose Reduction
measured Up to approximately 2 years
Permalink · ADCT's whole pipeline · Catalyst calendar · Every registered study · What changed